J&J drops $1.6B blood cancer collab

June 7, 2021

Johnson & Johnson is letting go of a collaboration deal with Netherlands-based argenx SE to develop a blood cancer treatment.

The deal, which was inked in 2018, focused on the development of an investigational antibody called cusatuzumab for a range of blood cancers including acute myeloid leukemia. The match-up originally included a $300 million upfront payment along with a $200 million equity investment in a deal that could have increased in value to $1.6 billion.

But after reviewing all of the data on cusatuzumab and evaluating the current standards of care, J&J decided to hand global rights to the drug back to argenx. 

Argenx said that phase 1b trial data on the treatment supported its continued development for acute myeloid leukemia.

Latest from Large Molecule